Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.

Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins

Biogen opened higher by around 10% on news of its Alzheimer's drug. By the end of day, BIIB stock gave up a bulk of its gains.

Potential Alzheimer’s Drug Not Enough to Excite Biogen Stock Investors

If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up

CAMBRIDGE, Mass., July  08, 2020  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that positive results from a Phase 1/2 study of tofersen (BIIB067) for the potential treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) were published in The New England Journal of Medicine. A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately two percent of all ALS cases.

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

Snap

Twitter

Snap, Nio, Biogen and Twitter were our top stock trades for Thursday. That said, let's see how the charts are setting up after some big moves.

4 Top Stock Trades for Thursday: TWTR, NIO, BIIB, SNAP

The biotech submitted a highly anticipated regulatory filing.

Why Biogen Stock Jumped Today

The market is cheering progress for the company's Alzheimer's disease candidate.

Biogen Shares Spike on Alzheimer's Update

JD.com

The Nasdaq once again led the way for the broader stock market.

Biogen Lifts Nasdaq to Near-Record; JD.com Leads China Internet Stocks Higher

Biogen (BIIB) recently announced that it will begin FDA approval on its Alzheimer’s disease drug aducanumab in the third quarter 2020.

Biogen: A Mix Of Growth And Stability

Biogen has asked the feds to let it market a potentially groundbreaking treatment for Alzheimer’s disease in the US, the company said Wednesday. The Massachusetts-based biotech firm asked the Food and Drug Administration for an expedited review of the drug known as aducanumab, which would be the first treatment to change the course of Alzheimer’s.

Biogen applies to market Alzheimer’s disease treatment in the US

Biogen Inc. (NASDAQ: BIIB) may be on track to be one of the first companies with a meaningful treatment for Alzheimer’s disease (AD), and this could have huge implications for the disease and the stock.

Biogen Could Still Have Massive Upside From Its Alzheimer’s Drug

Biogen stock popped Wednesday after the biotech giant asked the Food and Drug Administration to approve its controversial Alzheimer's treatment, aducanumab.
The post Biogen Pops After Asking FDA To Approve Controversial Alzheimer's Drug appeared first on Investor's Business Daily.

Biogen Pops After Asking FDA To Approve Controversial Alzheimer's Drug

Shares of Biogen BIIB, -0.53% jumped 7.4% in premarket trading on Wednesday after the drugmaker and Eisai Co.

Biogen's stock rises on submission to FDA for Alzheimer's drug application

CAMBRIDGE, Mass. and TOKYO, July  08, 2020  (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer’s disease. The completed submission followed ongoing collaboration with the FDA and includes clinical data from the Phase 3 EMERGE and ENGAGE studies, as well as the Phase 1b PRIME study. As part of the completed submission, Biogen has requested Priority Review. If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and would also be the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes.

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease

AbbVie

Which of these two drugmakers will outperform the other on the stock market moving forward?

Better Buy: AbbVie vs. Biogen

A patent ruling involving Biogen’s blockbuster drug weighed on share performance.

Why Biogen Shares Fell 12.9% in June

Biogen is more profitable, more innovative, and its stock may be undervalued to boot.

Forget Vertex, Biogen Is a Better Value Stock

Axsome Therapeutics

Eli Lilly

Demand for Alzheimer's medication is expected to grow as the population of older adults rises.

Should You Buy These 3 Stocks Tackling Alzheimer's Disease?

Southwest Airlines

Texas opened its bars and then closed them again. Apple Inc. (NASDAQ:AAPL) opened its stores and then re-shut 32 of them.

Biogen and Southwest Are on the Casualty List

BioNTech SE

Which stock wins in a matchup between these two coronavirus-focused biotechs?

Better Coronavirus Stock: Biogen or BioNTech?

Investors should be careful not to rely too heavily on valuation multiples.

Is This Bargain Biotech Stock a Treasure or a Trap?

AmerisourceBergen

DexCom

These are the health care stocks with the best value, fastest growth, and most momentum for July.

Top Health Care Stocks for July 2020

Biogen's anti-amyloid antibody does not meaningfully alter the natural course of Alzheimer's disease, by either halting or reversing disease progression based on P3 data.

Biogen's Statistical Gymnastics And PR Maneuvering Will Likely Turn Aducanumab Straw Into Mega Blockbuster Gold

Biogen Inc. (BIIB) Management Presents at SVB Leerink's CybeRx Series: 2nd Annual CNS Forum Conference (Transcript)

A patent appeal and a regulatory decision may produce huge rewards -- or losses.

News for Biogen Stock (BIIB)